Kei Muro

44.6k citations
601 papers · 17.1k · 7 hit papers · h-index 59

Impact in

  • Oncology top 0.1%
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • Pancreatic and Hepatic Oncology Research
    • Gastrointestinal Tumor Research and Treatment

Papers in

    • Colorectal Cancer Treatments and Studies 209
    • Cancer Immunotherapy and Biomarkers 65
    • Cancer Treatment and Pharmacology 52
    • Gastric Cancer Management and Outcomes 254
    • Lung Cancer Treatments and Mutations 73

Kei Muro

573 papers receiving 16.8k citations

Kei Muro's Hit Papers

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 2018 · 334 citations
3340+8+17Years since publication50010001.5k

Peers

Kei Muro
Comparison fields: 5 of 138
  • Oncology 7.4k
  • Gastroenterology 1.3k
  • Pulmonary and Respiratory Medicine 5.7k
  • Surgery 4.2k
  • Pathology and Forensic Medicine 1.3k
Replace Patrick Schöffski with:
Patrick Schöffski Belgium
Atsushi Ohtsu Japan
Antoine Adenis France
Narikazu Boku Japan
Stefano Cascinu Italy
G. Bodoky Hungary
Do‐Youn Oh South Korea
David P. Kelsen United States
Ian Chau United Kingdom
Ken Kato Japan
Kei Muro relative to Patrick Schöffski Belgium Patrick Schöffski's profile →
Citations per field
00.5×1.5×1.8×
Patrick Schöffski · 1×
Citations per year

Countries citing papers authored by Kei Muro

Since Specialization
Citations

This map shows the geographic impact of Kei Muro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Muro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Muro more than expected).

Fields of papers citing papers by Kei Muro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kei Muro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Muro. The network helps show where Kei Muro may publish in the future.

Co-authors

The 25 scholars most cited alongside Kei Muro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kei Muro Line = papers co-authored together Kei Muro links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 601 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hit paper breakdown →
20141743
2
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Hit paper breakdown →
2016854
3
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Hit paper breakdown →
2000608
4 2004469
5
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Hit paper breakdown →
2013382
6 1999364
7
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
Hit paper breakdown →
2017357
8
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Hit paper breakdown →
2018334
9 2011308
10
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Hit paper breakdown →
2017294
11 2010271
12 2012244
13 2007213
14 2013195
15 2004193
16 2019191
17 2010177
18 2010173
19 2004167
20 2019157

About Kei Muro

Kei Muro is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Gastroenterology and Molecular Biology, having authored 601 papers that have together received 17.1k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (254 papers), Colorectal Cancer Treatments and Studies (209 papers), Esophageal Cancer Research and Treatment (95 papers), Lung Cancer Treatments and Mutations (73 papers), Cancer Immunotherapy and Biomarkers (65 papers), Cancer Treatment and Pharmacology (52 papers), Gastrointestinal Tumor Research and Treatment (44 papers) and Cancer Genomics and Diagnostics (29 papers). The work is most often cited by research in Oncology (7.4k citations), Gastroenterology (1.3k citations), Pulmonary and Respiratory Medicine (5.7k citations), Surgery (4.2k citations) and Pathology and Forensic Medicine (1.3k citations). Kei Muro has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Atsushi Ohtsu, Yasuhiro Shimada, Takashi Ura, Yoshito Komatsu, Narikazu Boku, Kohei Shitara, Eric Van Cutsem, Shuichi Hironaka, Yasuhide Yamada and Hyun Cheol Chung. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, International Journal of Clinical Oncology, Japanese Journal of Clinical Oncology and Gastric Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact